Anthracycline, Trastuzumab, and Cardiovascular Toxicity

T. R. Cochran, V. I. Franco, R. Scully, S. E. Lipshultz

Research output: Chapter in Book/Report/Conference proceedingChapter


In cancer treatment, the pervasive late effects of radiation and chemotherapy limit their utility, especially in children, in whom treatment often leads to lifelong morbidity and excess mortality. Advances in understanding the molecular pathways related to tumorigenesis have led to the development of targeted therapies, but recurrent late effects, as in the case of trastuzumab, and unexpectedly high rates of cardiotoxicity highlight gaps in our understanding of drug pathways and the mechanisms of treatment toxicity. Here, we review the mechanisms of anthracycline activity in tumor and cardiac cells, as well as the clinical manifestations and their associated cardiotoxicity, prevention strategies, and monitoring recommendations. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.

Original languageEnglish (US)
Title of host publicationCardiovascular Toxicology
PublisherElsevier Inc.
Number of pages15
ISBN (Electronic)9780081006122
ISBN (Print)9780081006016
StatePublished - Jan 1 2018


  • Adverse effects
  • Antineoplastic antibiotics
  • Cancer survivorship
  • Cardiac biomarkers
  • Cardiomyopathy
  • Cardioprotection
  • Cardiotoxicity
  • Congestive heart failure
  • Dexrazoxane
  • Doxorubicin
  • Echocardiography
  • Epirubicin
  • Idarubicin
  • Late effects
  • Mitoxantrone
  • Monitoring
  • Neuregulin
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Anthracycline, Trastuzumab, and Cardiovascular Toxicity'. Together they form a unique fingerprint.

Cite this